3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
8
Tumor-Agnostic
3
Thoracic
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
2
Colorectal Neoplasms
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Melanoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Basal Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
40
Nivolumab
18
trametinib
13
Cyclophosphamide
13
dabrafenib
11
Vemurafenib
10
Interleukin-2
10
Ipilimumab
9
fludarabine
7
Docetaxel
7
fludarabine phosphate
6
cemiplimab
6
Paclitaxel
6
Cisplatin
6
Carboplatin
6
atezolizumab
5
Radiotherapy
5
Drug Therapy
5
Dacarbazine
5
Blood Specimen Collection
5
Biopsy
5
poly ICLC
4
binimetinib
4
Therapeutics
4
Psychiatric Rehabilitation
4
sotigalimab
3
montanide ISA 51
3
encorafenib
3
cobimetinib
3
budigalimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Folfox protocol
×
Dermatologic
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled